The diabetes treatment devices market includes tools used to manage diabetes, such as insulin delivery systems (e.g., insulin pens, pumps, and jet injectors) as well as blood glucose monitoring devices (including self-monitoring meters and continuous glucose monitoring systems). This market supports individuals with diabetes—both Type 1 and Type 2—by enabling accurate glucose tracking and effective insulin therapy. Market growth is primarily driven by the rising global prevalence of diabetes and increased awareness of the importance of disease management. Significant innovations like smart insulin pens, automated/artificial pancreas systems, and app-connected devices are enhancing precision and easing daily management. North America leads the market thanks to high healthcare spending and technology adoption, while the Asia-Pacific region is emerging rapidly due to rising incidence rates and expanding healthcare access.
According to Fortune Business Insights, the global diabetes treatment devices market was valued at USD 10.83 billion in 2018 and is projected to reach USD 22.83 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period. In 2018, North America dominated the market with a 40.44% share.
Top Companies in the Market
- F. Hoffmann-La Roche Ltd
- Tandem Diabetes Care, Inc.
- B. Braun Melsungen AG
- Medtronic
- BD
- Novo Nordisk A/S
- Abbott
- Sanofi
- Other players
Key Industry Development
In March 2021, F. Hoffmann-La Roche Ltd unveiled the Accu-Check Instant system, a cutting-edge blood glucose monitoring solution designed to support Roche’s integrated personalized diabetes management approach.
Market Drivers & Restraints
The market’s growth is propelled by multiple compelling forces. First and foremost is the rising prevalence of diabetes, notably the expanding pool of insulin-dependent type 1 patients, which amplifies demand for advanced insulin delivery devices. Additionally, technological advancements—from user-friendly insulin pens and self-monitored patch pumps to minimally invasive insulin delivery solutions—are reshaping patient experiences and driving adoption.
On the flip side, challenges such as high costs, regulatory hurdles, and supply chain complexities can restrain the pace of penetration—especially in lower-income regions (though these specifics come from the broader “Diabetes Care Devices” context, they reflect relevant headwinds).
Market Report Coverage
The Fortune Business Insights report offers a comprehensive landscape of the market, including prevalence and incidence data, trends around insulin delivery advancements (like artificial pancreas systems), mergers and acquisitions, pricing dynamics, technological innovations, key industry trends, pricing analysis, and competitive strategies adopted by leading players.
Market Competitive Landscape
Among the dominant players, Medtronic, F. Hoffmann-La Roche Ltd, and Tandem Diabetes Care, Inc. held significant revenue shares in 2018. These companies leverage extensive R&D investments, product innovation, and global distribution networks to maintain leadership. Other prominent players include BD, Sanofi, and a host of other competitors.
Market Segments
The market is segmented by:
- Product Types: Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Others.
- Distribution Channels: Institutional Sales (Hospitals, Clinics, Others) and Retail Sales (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
- Geography: North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Scandinavia, Rest of Europe), Asia Pacific (Japan, China, India, Australia, Southeast Asia, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa (South Africa, GCC, Rest of MEA).
Regional Insights
In 2018, North America led the market with a dominant share of 40.44%, amounting to approximately USD 4.38 billion. The region’s leadership is supported by strong R&D, favorable regulatory frameworks, and early adoption of minimally invasive insulin technologies.
The Asia-Pacific region is poised for rapid growth, driven by a sizable diabetic population, increasing awareness, and rising adoption of advanced, minimally invasive insulin delivery devices. Countries like China and India play a central role in this dynamic.
Meanwhile, Europe, Latin America, and Middle East & Africa are expected to see healthy growth, buoyed by increasing healthcare spending, rising diabetes prevalence, and expanding accessibility.
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/diabetes-treatment-devices-market-100777
Future Market Scope
Looking ahead to 2032, the market’s projected size of USD 22.83 billion reflects the sustained growth potential of this vital segment of diabetes care. Key growth levers include product innovation—especially in insulin delivery systems like smart pens, pumps, and integrated management platforms—and widening access in high-growth regions.
The March 2021 launch of Roche’s Accu-Check Instant system exemplifies how personalization and integrated solutions are shaping market dynamics. We can expect further collaborations, strategic launches, and technological integration to define the market’s future.
Conclusion
The diabetes treatment devices market stands at a pivotal juncture—poised for robust growth through 2032. With a projected CAGR of 5.5% and an impressive doubling in market value, the trajectory is clear. Leaders like Medtronic and Roche, backed by innovation and reach, are strengthening their positions, while Asia-Pacific and other emerging markets represent immense opportunity.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
